Trial Profile
A Retrospective cohort study to evaluate the safety, efficacy and Durability of the single tablet regimens (Triumeq®, Stribild®, Genvoya®, Eviplera®, Rezolsta®) in patients with HIV infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2018
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Cobicistat/darunavir (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 04 May 2018 New trial record
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases